Mesoblast Limited — Company profile
Healthcare · Biotechnology · Australia
Last price 15.67 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.12B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Details
| Name | Mesoblast Limited |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 108 |
| Founded | 2004 |
| Ceo | Silviu Itescu |
| Country | Australia |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| Isin | US5907174016 |
| Cusip | 590717401 |
| Cik | 0001345099 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Paul J. Simmons BSc, Ph.D. | Scientific Advisor to the Chief Executive Officer |
| Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board and Executive Director |
| Dr. Eric A. Rose M.D. | Chief Medical Officer and Executive Director |
| Paul Hughes BPHARM | Global Head of Corporate Communications and Joint Company Secretary |
| Anthony Wheal | Head of Human Resources |
| Geraldine Storton B.Sc., M.B.A., MMS | Head of Regulatory Affairs and Quality Management |
| Daniel Devine B.Sc., J.D., M.B.A | Head of Special Projects |
| Justin Horst B.S. | Head of Manufacturing |
| Dr. Fiona See Ph.D. | Senior Vice President and Head of Translational Research |
| Marcelo Santoro | Chief Commercial Officer |
Contact
| Address | 55 Collins Street, Level 38, Melbourne, VIC 3000, Australia |
| Phone | 61 3 9639 6036 |
| Website | https://www.mesoblast.com |